Non-alcoholic steatohepatitis (NASH) is a type of NAFLD (nonalcoholic fatty liver
disease), which is the condition with stored excess of fat in liver. NAFLD is characterized
by steatosis of the liver, and NASH is a necro-inflammatory process whereby the liver
cells become injured under steatosis.
Prevalence rate of NAFLD in China is estimated at 15.0%, or 208.5 million NAFLD patients,
in 2017, and is expected to increase as less exercise and other lifestyle changes
in the PRC population increase the risk of obesity.
Although there is a huge patient pool and unmet medical needs, currently there are
no approved NASH drugs in the world. We are develop in-house breakthrough therapies
for NASH focusing on novel targets.